Atorvastatin News and Research

RSS

Favorable decision for Ranbaxy on Atorvastatin patent in Canada

Ranbaxy Laboratories Limited announced that the Federal Court of Canada has handed down a favorable decision in the company's case against Pfizer by finding invalid Pfizer's Canadian atorvastatin patent CA 2,021,546.

28 Jan 2007

Pfizer stops all Torcetrapib trials

On December 2, 2006, FDA was notified that Pfizer will suspend a large, Phase 3 trial evaluating the investigational cardiovascular therapy torceptrapib/atorvastatin (T/A) due to an increased rate of mortality (death) in patients receiving the combination compared to those receiving atorvastatin alone.

4 Dec 2006

Pfizer provides opinion on European Lipitor patent

Pfizer has said that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent covering Lipitor.

30 Oct 2006

Spanish patent victory favoring Ranbaxy on Atorvastatin unaffected

Ranbaxy Laboratories Limited said today that recently, in two separate rulings, the Spanish courts (the Mercantile Court of Barcelona, No. 2) found Spanish patent ES 2,167,306 (counterpart of Pfizer's EP 409 281) to be invalid for lack of novelty.

30 Oct 2006

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Pfizer has announced that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy.

19 Oct 2006

Ranbaxy invalidates Pfizer's 281 patent in Holland

Ranbaxy Laboratories Limited (Ranbaxy) has announced that The District Court of The Hague has handed down a decision in Ranbaxy's case against (Pfizer) Warner-Lambert over the cholesterol-lowering drug, atorvastatin, which is marketed by Pfizer as Lipitor(R).

14 Sep 2006

Dutch court upholds Lipitor patent

Pfizer said today that the District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy.

13 Sep 2006

More aggressive treatment with statins necessary to lower LDL cholesterol in patients with coronary heart disease and metabolic syndrome

More aggressive treatment with statins is necessary to lower LDL (low-density lipoprotein) cholesterol in patients with coronary heart disease and metabolic syndrome, a syndrome composing of three cardiovascular risk factors according to an online article published today by The Lancet.

5 Sep 2006

Ranbaxy wins two additional Atorvastatin patents in Norway

Ranbaxy Laboratories Limited has announced that a Norwegian court handed down a favorable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway.

30 Aug 2006

Lipitor reduces the risk of a second stroke

Researchers have found that the drug Lipitor which is normally used to lower cholesterol, can cut the risk of a second stroke when used in double doses.

14 Aug 2006

Lipitor reduces stroke risk

In people who have experienced a stroke, but who have no known history of coronary heart disease, beginning regular treatment with the cholesterol-lowering drug atorvastatin soon after the stroke can reduce the risk of recurrent stroke by 16 percent

9 Aug 2006

Ranbaxy invalidates Pfizer's '995 Lipitor U.S. patent

Ranbaxy announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer.

2 Aug 2006

Pfizer's atorvastatin (Lipitor) patent safe

Pfizer Inc said today that a panel of the Court of Appeals for the Federal Circuit has upheld the exclusivity of the main patent covering atorvastatin, the active ingredient in Lipitor, maintaining patent protection for Lipitor in the U.S. until March 2010.

2 Aug 2006

Statins stop the replication of the hepatitis C virus

A new study shows that statins, which are typically used as anti-cholesterol medications, can inhibit the replication of the hepatitis C virus (HCV).

9 Jul 2006

NHS could save 2 billion pounds by switching to generic cholesterol lowering drugs

The NHS in England could save over £2bn in the next five years if doctors simply switched patients to cheaper generic cholesterol lowering drugs (statins), say two senior doctors in this week's British Medical Journal.

8 Jun 2006

Atorvastatin may increase new blood vessel formation

Systemic sclerosis (SSc), also known as scleroderma, is an uncommon and confounding disease characterized by excessive fibrous tissue formation and vascular abnormalities.

6 Jun 2006

Hydrophobic statins not associated with increased breast cancer risk

A report published in the Journal of the National Cancer Institute found that women who took statins--the widely used cholesterol lowering drugs--do not face an increased breast cancer risk as had been suggested by some previous studies.

6 Jun 2006

On the diabetes front the news is not good

According to newly published study more than 73 million Americans, one-third of the adult population either already have diabetes and don't even know they have it or are well on the way to getting it.

29 May 2006

Atorvastatin could prove an effective therapy for multiple sclerosis

Scientists at the University of California, San Francisco and Stanford University Medical Center are reporting compelling new evidence that the cholesterol-lowering drug atorvastatin could prove an effective therapy for preventing the progression of, and reversing the severity of, multiple sclerosis (MS).

20 Mar 2006

Best seller Lipitor shown to improve kidney function

According to drug maker Pfizer it's top selling product worldwide, the cholesterol lowering medication Lipitor (Atorvastatin) has been shown to improve kidney function in patients with heart disease.

13 Mar 2006